LA, S., AA, B., CD, B., SV, D., MS, E., KA, E., . . . SM, S. (2022). BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension. Pulmonary circulation, 12(2), e12063. https://doi.org/10.1002/pul2.12063
Chicago Style (17th ed.) CitationLA, Spikes, et al. "BREEZE: Open-label Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder as Tyvaso DPI™ in Patients with Pulmonary Arterial Hypertension." Pulmonary Circulation 12, no. 2 (2022): e12063. https://doi.org/10.1002/pul2.12063.
MLA (9th ed.) CitationLA, Spikes, et al. "BREEZE: Open-label Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder as Tyvaso DPI™ in Patients with Pulmonary Arterial Hypertension." Pulmonary Circulation, vol. 12, no. 2, 2022, p. e12063, https://doi.org/10.1002/pul2.12063.
